Axa
ACRS icon

Axa’s Aclaris Therapeutics ACRS Stock Holding History

Axa’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18,200
Closed -$286K – 1132
2022
Q3 		$286K Buy
+18,200
New +$287K ﹤0.01% 1047
2019
Q3 		– Sell
-263,888
Closed -$578K – 1292
2019
Q2 		$578K Sell
263,888
-334,272
-56% -$1.82M ﹤0.01% 1069
2019
Q1 		$3.58M Buy
598,160
+216,212
+57% +$1.43M 0.01% 730
2018
Q4 		$2.82M Hold
381,948
– – 0.01% 751
2018
Q3 		$5.55M Hold
381,948
– – 0.02% 642
2018
Q2 		$7.63M Buy
381,948
+87,250
+30% +$1.61M 0.03% 532
2018
Q1 		$5.16M Buy
294,698
+32,939
+13% +$698K 0.02% 642
2017
Q4 		$6.46M Buy
+261,759
New +$6.37M 0.03% 595

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Axa's ACRS Position: Q4 2022 in Review

Axa sold out of Aclaris Therapeutics (ACRS) in Q4 2022, closing a stake of 18,200 shares — an estimated $286K sold.

Axa first reported a position in ACRS in Q4 2017 and held it in 8 quarters. The position peaked at $7.63M in Q2 2018. 128 funds tracked by Wall St. Rank hold ACRS as of Q4 2022.

  • Axa reported no remaining Aclaris Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Axa sold 18,200 Aclaris Therapeutics shares in Q4 2022, an estimated $286K.
  • Axa first reported a position in Aclaris Therapeutics in Q4 2017 and held it in 8 quarters.
  • Axa's Aclaris Therapeutics position peaked at $7.63M in Q2 2018.
  • 128 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2022.

Based on Axa's 13F filing for Q4 2022, filed 14 Feb 2023.